メインコンテンツにスキップ

サターラ、科学的なイノベーションを加速させる予測を実現する人工知能企業であるVyasaを買収

Certara improves software capabilities by expanding into deep learning and data fabric PRINCETON, N.J.— 2023年1月4日 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT), today announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The acquisition will elevate Certara’s software by bringing state-of-the-art artificial intelligence (AI) capabilities to its end-to-end platform. “We are pleased to … Continued

Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase

Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares PRINCETON, N.J.— 2022年11月7日 — Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ(Nasdaq:CERT) はCERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and building transformational healthcare … Continued

Certara, University of Cape Town and Pharmacometrics Africa Partner on Fellowship Program in Africa for Applied Pharmacometrics Training

PRINCETON, N.J.— 2022年3月29日 — Certara, Inc, a global leader in biosimulation, and Pharmacometrics Africa NPC, today announced a partnership with the University of Cape Town (UCT) to support its fellowship program for doctoral-level scientists from Africa.  The Fellowship program builds scientific and leadership capability in the region by enhancing the skills of scientists and … Continued

1 of 2
Powered by Translations.com GlobalLink OneLink Software